Eli Lilly Stock Holds Support, Faces Weight-Loss Drug Rivals But Seen Strong Over Long Term
- Eli Lilly stock finding support at 21-day line, Wednesday’s high an early entry
- Shares clearing resistance, working on potential buy point at 800.78
- Weight-loss drug competition mounting from Viking, but seen as limited threat
- Zepbound and Wegovy expected to drive $37B in sales by 2029
- Relative Strength Rating of 95 puts Lilly stock in top 5% over last 12 months
